Edwards Lifesciences reports strong Q4 2025 results with 13.3% sales growth to $1.57B, driven by TAVR and TMTT performance ...

Edwards Lifesciences stock wavered Wednesday, though the heart-valve replacement maker issued a bullish outlook for 2026.

Edwards Lifesciences (NYSE:EW) develops medical devices for structural heart disease, transcatheter procedures, and critical care, highlighting operational performance in the NYSE Composite sector.

The heart valve specialist reported a second straight quarter of double-digit TAVR sales growth and credited recent study results with driving a “sense of urgency” for treating patients.

Edwards Lifesciences (NYSE:EW) reported fourth-quarter and full-year 2025 results that management characterized as strong, ...

Investors reacted positively to Edwards’ 2026 guidance with shares up 1.25% in after-hours trading following the announcement.

Just after the close of regular trading, Edwards Lifesciences released fourth quarter and full year 2025 financial results. During today's call, management will discuss the results included in the ...

IRVINE, Calif. - Edwards Lifesciences (NYSE:EW) shares climbed 5% after the structural heart disease specialist issued upbeat guidance that outweighed a slight earnings miss in its fourth quarter ...

Edwards Lifesciences logged lower profit in its latest quarter despite higher sales, boosted by growth in its transcatheter aortic valve replacement segment. The company on Tuesday posted a profit of ...

Edwards Lifesciences on Tuesday forecast 2026 profit above estimates, betting on robust demand for its artificial heart valves and other medical devices, sending its shares up 3% in after-hours ...

A jury ruled that Medtronic violated multiple antitrust laws over its use of restrictive contracts with healthcare providers ...